Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Therapeutics Pipeline Review, H2 2015 - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/msbwwx/vancomycinresista) has announced the addition of the "Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Overview
  3. Therapeutics Development
  4. Pipeline Products for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections - Overview
  5. Pipeline Products for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections - Comparative Analysis
  6. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections - Therapeutics under Development by Companies
  7. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections - Therapeutics under Investigation by Universities/Institutes
  8. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections - Products under Development by Companies
  13. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections - Products under Investigation by Universities/Institutes
  14. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections - Companies Involved in Therapeutics Development
  • CrystalGenomics, Inc.
  • Debiopharm International S.A.
  • iNtRON Biotechnology Inc.
  • Wockhardt Limited

For more information visit http://www.researchandmarkets.com/research/msbwwx/vancomycinresista

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases